AstraZeneca could have a viable vaccine by November
The week started with good news
from the US Food and Drug Administration (#FDA). The federal agency issued an
“emergency use authorization” (EUA) for convalescent plasma to be used as a
treatment for hospitalized #COVID-19 cases.
According to the FDA, there is
enough scientific evidence that showed that the antibody-rich plasma “may be
effective,” and the possible benefits outweigh the potential risks. "Today’s
action follows the FDA’s extensive review of the science and data generated
over the past several months stemming from efforts to facilitate emergency
access to convalescent plasma for patients as clinical trials to definitively
demonstrate safety and efficacy remain ongoing."
This EUA will facilitate the
distribution of convalescent plasma in the States and its use by healthcare
providers.
Ahead of the presidential
elections, this is seen as a victory for the Trump administration. Related to
the subject, President #Trump is considering fast-tracking AstraZeneca’s
COVID-19 vaccine candidate. He wants it done and available to Americans before
the election.
AstraZeneca’s potential #vaccine
produced a “strong immune response” during the first two phases of clinical
trials. Currently, it has advanced to Phase
III trials.
Following the announcement, the
company's stock price rose by nearly 4%.
Sources: marketwatch.com, thestreet.com
Maklumat ini disediakan untuk edaran umum. Ia tidak mengambil kira objektif pelaburan tertentu, keadaan kewangan atau keperluan tertentu dari mana-mana penerima.
Anda harus bebas menilai setiap produk kewangan dan mempertimbangkan kesesuaian produk kewangan sedemikian, dengan mengambil kira objektif pelaburan tertentu anda, keadaan kewangan atau keperluan khusus, dan berunding dengan penasihat kewangan bebas, sebelum berurusan dalam produk kewangan yang disebutkan dalam dokumen ini.
Maklumat ini tidak boleh diterbitkan, diedar semula, diterbitkan semula atau diedarkan secara keseluruhan atau sebahagian kepada mana-mana individu lain tanpa kebenaran bertulis daripada Syarikat terlebih dahulu.
Prestasi lalu tidak sentiasa menggambarkan prestasi atau kemungkinan masa depan. Sebarang pandangan atau pendapat yang dikemukakan hanyalah pandangan penulis semata-mata dan tidak mewakili za.capex.com.
JME Financial Services (Pty) Ltd, beroperasi sebagai ZA.CAPEX.COM, bertindak sebagai perantara antara pelabur dan Magnasale Trading Ltd, rakan kontrak untuk perbezaan yang dibeli oleh pelabur melalui ZA.CAPEX.COM, yang diberi kuasa dan dikawal selia oleh Cyprus Securities. dan Suruhanjaya Pertukaran dengan nombor lesen 264/15. Magnasale Trading Ltd adalah prinsip utama CFD yang dibeli oleh pelabur."
